Zepbound® and diarrhea

What the diarrhea row counts

A footnote under the US table, repeated in Canada’s, explains that the diarrhea heading merges two reported terms: diarrhea and frequent bowel movements ^[1][3]. Going more often than usual therefore counts even if stools are not watery, and anyone affected at least once during the 72 weeks is included, however briefly. The pool is SURMOUNT-1 and SURMOUNT-2, with 2,519 adults on Zepbound®, a quarter of whom had type 2 diabetes ^[1].

No document gives a figure for 2.5 mg: everyone passed through that dose as a four-week starter step, and no group stayed on it ^[1]. Nor is there a separate sleep apnea percentage; those trials are summarised only as similar to the weight pool ^[1]. The European rows below come from Mounjaro®, the name tirzepatide carries in the EU for both diabetes and weight management, because there is no Zepbound® EPAR ^[4].

Weight trials against diabetes trials

The same molecule produced more diarrhea in the weight setting. In SURMOUNT-1 the tirzepatide groups reported 18.7% to 23.0%, while the placebo-controlled diabetes trials summarised in the same European document ranged from 11.8% to 16.2% ^[4]. The placebo groups went the other way, 7.3% in SURMOUNT-1 against 8.9% in the diabetes pool, so the excess attributable to the drug was wider in people without diabetes ^[4]. Stomach and bowel reactions overall followed suit: 55.6% to 60.8% in SURMOUNT-1, compared with 37.1% to 43.6% in the diabetes trials ^[4].

None of the documents explains the difference, and the trials differed in design as well as in who took part, so the comparison describes rather than explains. For a Zepbound® user with type 2 diabetes, the US pool is the closest match, but the label does not print SURMOUNT-2’s diarrhea rate on its own ^[1]. The SURMOUNT-2 report names nausea, diarrhoea and vomiting as its most frequent adverse events, mostly mild to moderate, with few leading to stopping treatment (under 5%) ^[7]. Looking only at people without diabetes, Kommu and colleagues pooled six randomised trials and found diarrhea almost three times as likely on tirzepatide as on placebo (relative risk 2.92) ^[5].

When it appears and how it was handled in trials

The label groups diarrhea with nausea and vomiting: most of these events occurred while the dose was being stepped up and became less frequent over time ^[1]. It gives no typical duration and no stopping rate for diarrhea alone. Canada describes the stomach and bowel reactions in its three-trial weight pool as generally mild or moderate ^[3]. Lilly’s own patient page says the same about timing: most diarrhea arrived when people increased their dose and generally eased later ^[12].

A manufacturer-funded analysis of SURMOUNT-1 to -4 adds a practical detail. When participants needed an anti-diarrhea medicine, they most often began it during dose escalation, not months later ^[6]. Stomach and bowel side effects as a group were reported by 27.8% to 72.8% of people on tirzepatide across those trials, against 12.2% to 32.5% on placebo, and most were not serious ^[6].

Fluids, salts and the kidneys

Diarrhea takes out water and salts together. The EU information asks people on tirzepatide to avoid both fluid depletion and electrolyte disturbances, noting that older people may be more prone to complications ^[4]. The US label’s concern is the step after that: kidney injury reported after approval, sometimes needing dialysis, mostly in people dehydrated by stomach reactions, with kidney checks advised when such reactions occur, above all early in treatment and after increases ^[1]. The Zepbound® kidney page covers that warning in depth.

NIDDK lists feeling tired, dizzy or light-headed, and skin that does not flatten straight back after a pinch, among signs of dehydration, and adds greasy, foul-smelling stools as a sign of poor absorption ^[9]. It notes that people who are pregnant, over 65, taking antibiotics or living with a weakened immune system are more likely to run into problems from diarrhea and should stay in touch with their doctor ^[9].

Why tirzepatide can loosen stools

What the label supports: tirzepatide acts on GIP and GLP-1 receptors, cuts calorie intake and delays stomach emptying, and diarrhea clusters in the escalation weeks ^[1]. The label does not describe a mechanism for diarrhea itself ^[1].

What reviews propose: a 2025 review of stomach symptoms in obesity treatment reported such effects in 65% to 84% of trial participants on liraglutide, semaglutide or tirzepatide, and attributed them mainly to altered stomach motility and hormone-driven changes in appetite signalling ^[8]. It is a narrative review that collects other studies; it did not measure how tirzepatide changes the bowel.

General background: NIDDK defines diarrhea as loose, watery stools three or more times a day, or more often than is normal for you, often with urgency, cramping and sometimes loss of control ^[9]. That breadth matches the label’s choice to count frequent bowel movements under the same heading.

Other things that cause diarrhea

NIDDK names viral gastroenteritis, food poisoning and medicine side effects as the most common causes of sudden diarrhea ^[9]. Several are worth checking against the changes people often make when they start a weight-loss medicine. Sugar alcohols in sugarless gum and sweets can loosen stools in some people, and problems digesting lactose, fructose or table sugar can cause diarrhea after the foods that contain them ^[9][11].

Longer-lasting diarrhea has a wider list, including infections, food allergies, digestive tract disorders and abdominal surgery, and in people with diabetes, nerve damage affecting the gut (autonomic neuropathy) ^[9]. Diarrhea that runs for weeks deserves its own investigation rather than being assumed to be the injection.

Practical steps from Lilly and the NIH

Lilly’s Zepbound® page asks people with diarrhea to talk to their doctor and suggests interim measures; NIDDK adds detail on fluids, food and medicines ^[10][11][12]. Your prescriber remains the person who decides about your dose.

• Drink plenty of fluids, with water generally preferred; NIDDK adds broths, sports drinks and oral rehydration solutions to replace electrolytes ^[10][12].
• If you have diabetes or kidney disease, or are older, ask your doctor before using oral rehydration solutions, since a specific product or amount may suit you better ^[10].
• Limit dairy and choose bland foods such as chicken broth, rice or carrots ^[12]. NIDDK also suggests avoiding caffeine, very sugary drinks and sweets, sugar alcohols and high-fat foods while diarrhea lasts, but says most experts do not advise a restricted diet beyond that, or fasting ^[11].
• NIDDK says adults can usually manage sudden diarrhea with over-the-counter loperamide or bismuth subsalicylate; these are generally avoided when stools are bloody or there is a fever, and a doctor is needed if things get worse or drag on beyond 2 days despite them ^[10]. Check with a pharmacist first: by delaying stomach emptying, Zepbound® may alter the uptake of anything swallowed as a tablet ^[1].
• A food and bowel diary can help you and your doctor spot triggers ^[11].

Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.

When to get help